ASH News Daily 2017 - Issue 2 - B-23

ASH News Daily

Sunday, December 10, 2017

Page B-23
®

career-enhancement
awardS

ASH Scholars
«« From Page B-22

cell biological pathways leading to
platelet formation from megakaryocytes. Currently, her laboratory is
interested in revealing how different
disease states alter megakaryocytes,
and how these changes are ultimately manifested in their platelet progeny. Specifically, Dr. Machlus is in-

terested in how different mediators
of inflammation, such as the cytokine CCL5, alter hematopoietic stem
cell differentiation, megakaryocyte
maturation, and ultimately, platelet
production. These studies can lead
to novel approaches to treat thrombocytopenia through manipulation
of platelet number and function by
targeting their precursor cells, megakaryocytes.

training and developed expertise
in atomic force
microscopy-a
high-resolution
microscopy method with a wide
spectrum of applications in biology.
She studied early
stages of fibrin polymerization at the single molecule
level using atomic force microscopy
and visualized flexible and unstructured αC regions of fibrinogen for
the first time. In 2015, she joined the
laboratory of Dr. John Weisel at the

Anna Protopopova, PhD
Dr. Protopopova completed her
PhD in physics at Lomonosov Moscow State University in Russia. During that period, she received specific

Visit Booth #2233
and
Product Theater #4
Sunday, Dec 10, 11:30 AM - 12:30

University of Pennsylvania School
of Medicine as a postdoctoral fellow. Dr. Protopopova's work is focused on biophysical and molecular
structural studies of blood coagulation. Her most recent work revealed
that trimming of the fibrinogen αC
regions slows down fibrin formation
and suggested a purely kinetic effect
of the αC regions on fibrin architecture. The ASH Scholar Award will
support her work to characterize
the mechanical properties of blood
clots and thrombi at the molecular level (i.e., at the level of fibrin
»» ASH SCHOLARS Page B-24

Including pediatric patients with relapsed
or refractory CD33-positive AML

Find out more at

Access and support

MylotargHCP.com

1-877-744-5675

Adverse Cytogenetics: In a subgroup analysis in ALFA-0701, the addition of MYLOTARG to
standard combination chemotherapy did not improve event-free survival in the subgroup
of patients having adverse-risk cytogenetics. For patients being treated with MYLOTARG
in combination with daunorubicin and cytarabine for newly diagnosed de novo AML, when
cytogenetics testing results become available consider whether the potential benefit of
continuing treatment with MYLOTARG outweighs the risks for the individual patient.
Embryo-Fetal Toxicity: MYLOTARG can cause embryo-fetal harm when administered to a
pregnant woman. Advise patients of reproductive potential to use effective contraception during
and for 3 and 6 months following treatment for males and females, respectively. Apprise pregnant
women of the potential risk to the fetus. Advise women to contact their healthcare provider if they
become pregnant or if pregnancy is suspected during treatment with MYLOTARG.
Adverse Reactions: The most common adverse reactions (greater than 15%) were hemorrhage,
infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash,
and mucositis.
Contraindications: Hypersensitivity to MYLOTARG or any of its components. Reactions have
included anaphylaxis.
Please see brief summary of Full Prescribing Information, including BOXED WARNING,
on the following page.
Reference: 1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.
PP-MYL-USA-0115

F:7.625"

Printed in USA/November 2017

T:10"

QT Interval Prolongation: QT interval prolongation has been observed in patients treated
with other drugs containing calicheamicin. When administering MYLOTARG to patients who
have a history of or predisposition for QTc prolongation, who are taking medicinal products
that are known to prolong QT interval, and in patients with electrolyte disturbances, obtain
electrocardiograms and electrolytes prior to the start of treatment and as needed during
administration.

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2